Trial Profile

Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMG-305 (Primary)
Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Uterine cancer
Focus Adverse reactions; First in man
Sponsors Amgen

Most Recent Events

20 Feb 2025 Planned End Date changed from 22 Sep 2027 to 12 Feb 2028.
20 Feb 2025 Planned primary completion date changed from 18 Jan 2027 to 10 Jun 2027.
02 Dec 2024 Planned number of patients changed from 260 to 220.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com